Incorporating plausible surrogate variates, a general class of incomplete multiresponse designs for clinical trials is considered. In this context, the basic differences between the conventional linear models and survival analysis models are discussed thoroughly. Along with some parametric and semi-parametric procedures, suitable nonparametric ones are considered, and the related asymptotic theory is presented.
Introduction
In clinical trials, from epidemiological perspectives, often, information is gathered on more than one response variable, and, in addition, on relevant concomitant variables too. Nevertheless, from clinical or medical perspectives, it is not uncommon to single out one of the response variates as the most important (or relevant) one, termed the primary variate (although, in some cases, there may be stringent cost constraints associated with its precise measurement). The multitude of other response variates through their mutual dependence can cast light on the primary variate too, and hence, their simultaneous measurements generally lead to comparatively more precise statistical conclusions. On the other hand, based on other practical considerations, such as relative cost, ease and/or precision of measurement, it may not be very convenient to include the entire battery of simultaneous measurements on all the response variates (as well as the covariates). For this reason, often, an incomplete multiresponse design (imd) or a hierarchical design (hd) is adopted. In the latter design, there is an hierarchy on the response variates in the sense that there is a (partial) ordering with respect to the number of experimental units on which their measurements are recorded. For example, suppose that there are p{~1) response variates, denoted by Y 1 ,. .., Yp' respectively. On a smallest set, say Sl' of experimental units, all these p responses are measured simultaneously; there is a larger set, say S2' such that Sl c S2' and on the subset S2 \ Sl' Y 2 ,..., Yp are recorded (not Y1)' and so on. For the largest set Sp' such that Sl C S2 C ... eSp' on Sp \ Sp-1' only Yp is recorded; Sp_1 \ , Y p-1' Yp are recorded and so on. Such a multiresponse design, determined by {Sp"'" Sp} along with the inherent nesting:
Sl C S2 C ... esp' is termed a hierarchical design [viz., Roy, Gnanadesikan and Srivastava (1971, Ch. 8) ]. It may not be always desirable {or practical to impose the basic hierarchy condition mentioned above [vis., missing observation (response) problem in multiresponse data]. Nevertheless, it may be feasible to incorporate some incomplete response designs wherein the set Y= {Y 1 ,..., Yp} can be partitioned into various subsets {Y i1 ,... , Vi)' 1~r~p, 1 i 1 <... < i r~p , such that these subsets are adopted for possibly different number of experimental units. For example, for p=2, we have three possible subsets {Yd, {Y 2 } and {Y 1 , Y 2 }, and possibly different designs (say, 01' 02 and 012) may be chosen for these subsets. Recall that in clinical trials one may be primarily interested in a comparative study of a placebo and one or more treatments, so that the designs {O} are chosen in the conventional sense with due emphasis on these treatments.
In clinical trials, a primary (response) variate, in spite of being the most relevant one, may encounter some basic problems regarding its precise measurement (due to excessive cost or other limitations), and, therefore, it is not uncommon to make use of a very closely related (but, presumably, relatively less expensive) variable (say Yo)' which is termed a sur'Togate variate. Generally, surrogate variates do not contain as much information as contained in the primary variate (say, Y 1 ), but their use may greatly enhance the scope of the clinical trial (subjected to some cost and time constraints).
The use of such surrogate variates (response variables) in clinical trials (or medical investigations, in general) has generally been accepted by the allied medical community and has caught the attention of statisticians as well. A nice account of such uses (and abuses too) from a statistical perspective is given in a set of articles published in Statistics in Medicine, vol. 8, No. 2 (1989) . For some more recent statistical work, we also refer to Pepe (1992) , where other references are cited.
The primary objective of the current study is to focus on the design and analysis aspects of a general class of incomplete multiresponse designs, adoptable in dinical trials, which incorporate an appropriate surrogate variate to enhance statistical information without escalating (much) the cost of experimentation. The conventional surrogate model (incorporatin~~a validation sample) considered by Pepe (1992) can be characterized as a special case of an imd wherein one has only one primary variate and a surrogate variate, and moreover, only a completely randomized design (treatment wise) is envisaged in her work. In Section 2, we formulate an imd incorporating a surrogate variate in a more general setup, and study various aspects of such a design.
In spite of the isomorphism of design aspects, there is a basic difference between a conventional linear model and a so called regression model in clinical trials. This is apparent from the respective formulation of statistical functions on which inference is to be dllawn in a valid and yet reasonably efficient manner. This may generally limit the scope of applicability of standard parametric procedures in such imd with surrogate variates. In that respect, semi-parametric models fare well, and in Section 3, we provide an outline of both such procedures. Our main concern is to develop appropriate nonparametric procedures which may not need the basic (and somewhat stringent) regularity conditions inherent in a parallel semi-parametric model. We propose to defer most of these technicalities to a subsequent communication. However, for the sake of illustration, in Section 4, we consider a simple imd (with one primary variate and a surrogate variate), and discuss the related nonparametrics in some detail. designs (primarily to draw statistical conclusions in an efficient manner) {D} may depend very much on the nature of the response variates as well as concomitant variates pertaining to these subsets. As in Roy, Gnanadesikan and Srivastava (1971, Ch. 8) , we may allow these designs to be of quite general form. However, such designs are to be set primarily on the basis of clinical factors, and as such, may be quite different from the conventional agricultural ones (where a comparatively more controlled setup can be taken for granted). There is a further fundamental difference between the two setups, and this will be discussed in detail in the next section.
The hierarchical scheme in (2.3) -(2.4) is based on an ordering of the primary variates (i.e., the coordinates of Yare important in their own way (viz, they may stand for some endpoints which may be all of serious concern). In such a situation, some of the basic appeals of a (response wise) hierarchical design may be lost, and we may need to incorporate alternative designs which allow some flexibility in this respect. If we assume that all the q(~1) surrogate response variates are relatively easy to be recorded for the experimental units, there seems to be no good reason to drop them. Thus, response wise incomplete blocking may be solely applied to Y. As in Section 1, we denote by P = {I, ..., p} and consider the totality of subsets of P, defined by i r = {i l ,.., ir}' for all possible 1~i l < ... < i r~p and r = 0, 1,..., Pi i o = O. Thus, we would have a total number 2 P subsets of P.
Determined mostly by clinical and other extraneous considerations, we consider a proper subset Po of P, defined by (2.5) Then the set S = So of totality of experimental units is partitioned into a system where the first set refers to the response wise design set, while the other one for the treatment wise design set. Obviously, we shall assume that the cardinality of flo is greater than one, and also, we shall exclude the null set i o from 1P 0 ' unless we intend to have a set of experimental units where only the surrogate response variates (and covariates) are to be recorded. The design considered by Prentice (1989) is a special case of p = 1, q = 1; 1P0 refers to the set of no primary index and S (Po) =So is the entire set of experimental units where only the surrogate variate is recorded. Pepe (1992) considered the case of p = 1, q = 1 and i o = {O} , i 1 = {I}, so that one has a subset containing only the surrogate response, while a second subset contains both the primary and surrogate variates
(validation sample).
Thus, in our formulation, we have a general class of imd's {S(Po), D(lP o )} , which may also be adoptable in a more general multiresponse setup (incorporating surrogate variates). In this manner, our findings extend the basic results of Roy, Gnanedesikan and Srivastava (1971, Ch. 9 ) to clinical trials (having possibly multiple surrogate endpoints). We may reiterate that unlike the case in conventional agricultural experiments, the choice of the so called optimal (or nearly optimal) designs of the type (2.8) may depend heavily on the clinical aspects (relating to the cost and/or difficulty of obtaining measurements on the response variates), and hence, a "cost-benefit" approach may as well be incorporated in this setup. This is a potential area of active research for biostatisticians as well as clinical scientist, and it is rather an immature opportunity to go into this realm in the current study, Srivastava (1966 Srivastava ( , 1968 for some general discussion of the main issues involved in imd's, when there is no surrogate endpoint, and one has the conventional multivariate general linear model (mglm) setup in mind. The mglm coupled with the traditional assumption of the multinormality of the error vectors enable us to formulate the statistical models in a finite-dimensional parametric setup. We refer to Ch.
9 (Sections 9.2 and 9.3) of Roy, Gnanadesikan and Srivastava (1971) for an excellent account of statistical analysis of general imd's, wherein the multi-normality of the error vectors and the mglm structure both play vital roles. For possible departures from either of these two basic assumptions, even to a small extent, there can be serious effects on the validity and efficiency of their prescribed solutions. Or, in other words, for imd's, the standard parametric statistical analysis is likely to be much more nonrobust compared to the usual complete block (response) designs. This set I may be termed a surrogate set. This set I fails to provide any information on the relationship between Y and X, which is very much needed in drawing conclusions on the behavior of Y from that of X. For this reason, we may also consider another subset 1* (disjoint from I), such that for i f 1*, we record measurements on Y, X and Z all; this may be termed a validation sample.
We may refer to Pepe (1992) ..
so that we have a hierarchical design. We may also extend it to an imd by considering a third subset, say 10, where we have measurements on (Y, Z) (but not X). In a hierarchical design,~( z ) may be estimated from the data set pertaining to I and 1P( . ) from the set 1*. In an imd, 8( z ) may be estimated from the set 1°,~( z ) from I and 1P{.) from 1*. For simplicity of presentation, we consider explicitly the case where 8( . ) and~( . ) are conditional quantiles, and the theory extends directly to more general fun<:tionals. As a surrogate variate is essentially a substitute for the primary variate, following Prentice (1989) , it seems reasonable to require a surrogate for some true endpoint to have the potential to yield unambiguous information about differential treatment effects on the true endpoint. Hence, Prentice (1989) defined a surrogate endpoint to be a "response variable for which a test of the null hypothesis of no relationship to the treatment groups under comparison is also a valid test of the corresponding null hypothesis based on the true endpoint." To judge its relevance in the current context, let us partition the covariate vector Z as (Z(l), Z(2», where Z{l) contains the information on the treatment levels (mostly through dummy (nonstochastic) vectors, while Z(2) contains information on the genuine concomitant variates, some of which may as well be stochastic in nature. In the simplest model of 'placebo vs. treatment', often, Z (2) is taken as null, and Z{l) assumes only the two possible values (O for placebo, and 1 for treatment). for all Z{l) and Z(2). If the null hypothesis is not tenable, the alternative one may relate to one -or two-sided discrepancy of the 8's. In this respect, we may formulate (4.5) for all Z{l) and Z(2), and hence we may require the "testabilityr.' of (4.4) through (4.5). This may often call for a 'concordance' relation between the 0(·) and~(.). Typically, if contrary to (4.4), O(Z(l), Z(2)) depends on Z(l), then for the two nonidentical values, say, ZP) and Z~l), should have the same sign, (4.6)
..
• and moreover, a divergence in (4.4) should be somewhat isomorphic to that in (4.5), although it need not be a strictly linear pattern. If testing of a null hypothesis of no treatment effect is our primary goal, then based on a surrogate endpoint, a variety of nonparametric or semi-parametric tests can be constructed. Among these, the partial likelihood approach is quite popular, although genuine rank tests based on appropriate martingale characterizations [vis., Chapter 11 of Sen (1981) ] can as well be extended to such imd's. There has been some attempts to restructure the Prentice (1989) formulation of a surrogate end-point [vis., Pepe (1992) ], and partial likelihood or rank based tests work out neatly in such a case too. However, one may generally need to motivate such tests through the multivariate permutation principle [developed in detail in Chatterjee and Sen (1964) where nvO is the sample size of the subset of 1* for which Z == 0, and letting n vl be the parallel (4.10) and where the two (asymptotic) dispersion matrices r o and r l may both be consistently estimated from the validation subsets (when nvo and n vl are both large). In a variety of situations, it may even be quite plausible to assume that r l = r 2 = r (say), so that r may be estimated with a better rate of convergence. Likewise, if n. o and n al stand respectively for the sample sizes for the subsets of I for which Z = 0 and 1, then we have . .
I.
(4.13) (4.14)
where the regression coefficients Po and PI are to be obtained by the classical (normal theory) linear inference procedures by using the estimates of r o , r l ' ro" and rl.t. Essentially, (4.13) and (4.14)
incorporate adjustments to (4.9) and (4.10) based on the additional information in (4.11) and (4.12).
This procedure extends directly to the case where Z(l) may have more than 2 values (as is the case with the usual more than one treatment vs. placebo studies). The picture becomes somewhat more complex when the concomitant vector Z(2) contributes additional variation in the outcome. If Z (2) contains coordinate variables which assume only discrete (or categorical) mass points (viz., smoking vs. This procedure can be repeated for various X o of particular interest. We may refer to Gangopadhyay and Sen (1992 a, b) for some details of the related statistical theory. In this context, the choice of k (relative to n vo etc.) is an important task. Unlike in (4.9), (4.10), (4.11) or (4.12), we do not have a "square root n" order of convergence; they are typically of the order n a for some a~2/5. Also, for a = 2/5, the bias term may not be negligible, even asymptotically. As such, generally a is chosen as less that 2/5 [vis., Theorem 3.1 of Gangopadhyay and Sen (1992a) ] .
We conclude this section with some remarks on the choice of the validation subset 1 
and consider the functional
Similarly, for the validation set 1*, we define pictures. As a partial remedy it may be better to extend the validation set 1* by incorporating some additional observations for which the Xi are~Xo and then recording the Y i for them as well. This will enable one to estimate the relationship between {L(z) and {R(z) in a natural nonparametric way, and also the relationship between O(z) and {L(z), {R(z) can be estimated in a nonparametric fashion from this extended validation set. From robustness considerations, we would endorse such a validation set 1* instead of the left truncated one considered before. In this context, optimal design problems are quite important ones to study systematically, and we propose such studies for future research.
However, in passing, we may stress the importance of a proper selection of a validation set 1* which should not only meet the practicality of the measurements of the primary and surrogate variates in the given context but also be capable of eliminating bias and inefficiency to the extent possible. Thus, they should be robust. Therefore optimality (even in an asymptotic setup) of such clinical designs should not only take into consideration the relevant imd factors but also robustness of the underlying model. Naturally, such solutions are generally more complex. Nevertheless, they should not be outside the reach of statisticians primarily working in complex (multicenter) clinical trials. Finally, it may also be possible to have for a primary endpoint, a set of surrogate endpoints, so that X/s are p-vectors for some p~1. Because of some technical problems in defining a multivariate quantile function (other than as a vector of the marginal quantiles), it may be wiser to consider a cutting function X; = h(X i ) [when the Xi are p-vector] and treating the X; as the surrogate variate. The choice of h( . )
may not be that evident, but from various clinical and other extrameous considerations, often, this can be made conveniently. Once, this is accomplished, we have no problem in incorporating the theory developed earlier to provide the desired methodology. The choice of an optimal cutting function may therefore have a significant role in the contemplated design and statistical analysis aspects of the study.
